The Journal of Nutritional Biochemistry
Volume 21, Issue 9 , Pages 818-826 , September 2010

4-Hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity

  • Stefania Pizzimenti

      Affiliations

    • Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Torino, Italy
    • Corresponding Author InformationCorresponding author. Dipartimento di Medicina ed Oncologia Sperimentale, Sezione di Patologia Generale, 10153 Torino, Italy. Tel.: +39 011 6707763; fax: +39 011 6707753.
    • S.P. and E.M. have contributed equally to the studies present in this manuscript.
    • ,
  • Elisa Menegatti

      Affiliations

    • Department of Experimental Medicine and Oncology, Section of Clinical Pathology, University of Turin, 10125 Torino, Italy
    • S.P. and E.M. have contributed equally to the studies present in this manuscript.
    • ,
  • Daniela Berardi

      Affiliations

    • Department of Experimental Medicine and Oncology, Section of Clinical Pathology, University of Turin, 10125 Torino, Italy
    • ,
  • Cristina Toaldo

      Affiliations

    • Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Torino, Italy
    • ,
  • Piergiorgio Pettazzoni

      Affiliations

    • Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Torino, Italy
    • ,
  • Rosalba Minelli

      Affiliations

    • Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Torino, Italy
    • ,
  • Barbara Giglioni

      Affiliations

    • Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), 20090 Segrate (Milano), Italy
    • ,
  • Angelo Cerbone

      Affiliations

    • Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Torino, Italy
    • ,
  • Mario U. Dianzani

      Affiliations

    • Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Torino, Italy
    • ,
  • Carlo Ferretti

      Affiliations

    • Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, 10125 Torino, Italy.
    • ,
  • Giuseppina Barrera

      Affiliations

    • Department of Medicine and Experimental Oncology, Section of General Pathology, University of Turin, 10125 Torino, Italy

Received 20 March 2009 ,Revised 8 June 2009 ,Accepted 15 June 2009.

References 

  1. Dupertuis YM, Meguid MM, Pichard C. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care. 2007;10:427–432
  2. Law M. Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach. Am J Clin Nutr. 2000;72:3–11
  3. Barrera G, Pizzimenti S, Dianzani MU. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med. 2008;29:1–8
  4. Eckl PM. Genotoxicity of HNE. Mol Aspects Med. 2003;24:161–165
  5. Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis. 2002;23:1781–1789
  6. Leonarduzzi G, Robbesyn F, Poli G. Signaling kinases modulated by 4-hydroxynonenal. Free Radic Biol Med. 2004;37:1694–1702
  7. Awasthi YC, Sharma R, Sharma A, Yadav S, Singhal SS, Chaudhary P, et al. Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death. Free Radic Biol Med. 2008;45:111–118
  8. Barrera G, Di Mauro C, Muraca R, Ferrero D, Cavalli G, Fazio VM, et al. Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation. Exp Cell Res. 1991;197:148–152
  9. Fazio VM, Barrera G, Martinotti S, Farace MG, Giglioni B, Frati L, et al. 4-Hydroxynonenal, a product of cellular lipid peroxidation, which modulates c-myc and globin gene expression in K562 erythroleukemic cells. Cancer Res. 1992;52:4866–4871
  10. Rinaldi M, Barrera G, Spinsanti P, Pizzimenti S, Ciafrè SA, Parella P, et al. Growth inhibition and differentiation induction in murine erythroleukemia cells by 4-hydroxynonenal. Free Radic Res. 2001;34:629–637
  11. Barrera G, Muraca R, Pizzimenti S, Serra A, Rosso C, Saglio G, et al. Inhibition of c-myc expression induced by 4-hydroxynonenal, a product of lipid peroxidation, in the HL-60 human leukemic cell line. Biochem Biophys Res Commun. 1994;203:553–561
  12. Barrera G, Pizzimenti S, Serra A, Ferretti C, Fazio VM, Saglio G, et al. 4-hydroxynonenal specifically inhibits c-myc but does not affect c-fos expressions in HL-60 cells. Biochem Biophys Res Commun. 1996;227:589–593
  13. Pizzimenti S, Barrera G, Dianzani MU, Brüsselbach S. Inhibition of D1, D2, and A-cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal. Free Radic Biol Med. 1999;26:1578–1586
  14. Barrera G, Pizzimenti S, Laurora S, Moroni E, Giglioni B, Dianzani M. U. 4-Hydroxynonenal affects pRb/E2F pathway in HL-60 human leukemic cells. Biochem Biophys Res Commun. 2002;295:267–275
  15. Pizzimenti S, Laurora S, Briatore F, Ferretti C, Dianzani MU, Barrera G. Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radic Biol Med. 2002;32:233–245
  16. Laurora S, Tamagno E, Briatore F, Bardini P, Pizzimenti S, Toaldo C, et al. 4-Hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line. Free Radic Biol Med. 2005;38:215–225
  17. Matés JM, Segura JA, Alonso FJ, Márquez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol. 2008;82:273–299
  18. Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008;7:1875–1884
  19. Chen ZH, Niki E. 4-hydroxynonenal (4-HNE) has been widely accepted as an inducer of oxidative stress. Is this the whole truth about it or can 4-HNE also exert protective effects. IUBMB Life. 2006;58:372–373
  20. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003;42:318–343
  21. Pizzimenti S, Briatore F, Laurora S, Toaldo C, Maggio M, De Grandi M, et al. 4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radic Biol Med. 2006;40:1578–1591
  22. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 1995;155:3711–3715
  23. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of Life-Span by Introduction of Telomerase into Normal Human Cells. Science. 1998;279:349–352
  24. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015
  25. Bestilny LJ, Brown CB, Miura Y, Robertson LD, Riabowol KT. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res. 1996;56:3796–3802
  26. Xu D, Gruber A, Peterson C, Pisa P. Suppression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia. 1996;10:1354–1357
  27. Xu D, Popov N, Hou M, Wang Q, Björkholm M, Gruber A, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci. U. S. A. 2001;98:3826–3831
  28. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787–791
  29. Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer. 1997;21:233–300
  30. Kanamaru T, Tanaka K, Kotani J, Ueno K, Yamamoto M, Idei Y, et al. Telomerase activity and hTERT mRNA in development and progression of adenoma to colorectal cancer. Int J Mol Med. 2002;10:205–210
  31. Boldrini L, Faviana P, Gisfredi S, Donati V, Zucconi Y, Ursino S, et al. Evaluation of telomerase in the development and progression of colon cancer. Int J Oncol. 2002;10:589–592
  32. Biasi F, Mascia C, Poli G. TGFB1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr. 2007;2:233–243
  33. Pierre F, Tache S, Guéraud F, Rerole AL, Jourdan ML, Petit C. Apc mutation induces resistance of colonic cells to lipoperoxide-triggered apoptosis induced by faecal water from haem-fed rats. Carcinogenesis. 2007;28(2):321–327
  34. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81–128
  35. Borras C, Esteve JM, Vina JC, Sastre J, Vina J, Pallardo FV. Glutathione regulates telomerase activity in 3T3 fibroblasts. J Biol Chem. 2004;279:34332–34335
  36. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, et al. Sp-1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000;28:669–677
  37. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8:137–142
  38. Chantret I, Barbat A, Dussaulx E, Brattain MG, Zweibaum A. Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res. 1988;48:1936–1942
  39. Gelmini S, Caldini A, Becherini L, Capaccioli S, Pazzagli M, Orlando C. Rapid, quantitative nonisotopic assay for telomerase activity in human tumors. Clin Chem. 1998;44:2133–2138
  40. Owens L, Belcher RVA. colorimetric micro-method for the determination of glutathione. Biochem J. 1965;94:75–79
  41. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 1999;59:826–830
  42. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008;99:1528–1538
  43. Shagin DA, Barsova EV, Yanushevich YG, Fradkov AF, Lukyanov KA, Labas YA, et al. GFP-like proteins as ubiquitous metazoan superfamily: evolution of functional features and structural complexity. Mol Biol Evol. 2004;21:841–850
  44. Cerbone A, Toaldo C, Laurora S, Briatore F, Pizzimenti S, Dianzani MU, et al. 4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. Free Radic Biol Med. 2007;42:1661–1670
  45. Calonghi N, Boga C, Cappadone C, Pagnotta E, Bertucci C, Fiori J, et al. Cytotoxic and cytostatic effects induces by 4-hydroxynonenal in human osteosarcoma cells. Biochem. Biophys Res Commun. 2002;292:1502–1507
  46. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer. 2001;91:644–649
  47. Liu K, Hodesn RJ, Weng N. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol. 2001;166:4826–4830
  48. Toogun OA, Dezwaan DC, Freeman BC. The hsp90 molecular chaperone modulates multiple telomerase activities. Mol Cell Biol. 2008;28:457–467
  49. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 2001;269:1–12
  50. Gunes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 2000;60:2116–2121
  51. Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27–38
  52. Spengler ML, Guo LW, Brattain MG. Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation. Cell Cycle. 2008;7:623–630
  53. Bollmann FM. The many faces of telomerase: emerging extratelomeric effects. Bioessays. 2008;30:728–732
  54. Rahman R, Latonen L, Wiman KG. hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene. 2005;24:1320–1327
  55. Lai SR, Cunningham AP, Huynh VQ, Andrews LG, Tollefsbol TO. Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop. Exp Cell Res. 2007;313:322–330
  56. Jagadeesh S, Banerjee PP. Telomerase reverse transcriptase regulates the expression of a key cell cycle regulator, cyclin D1. Biochem Biophys Res Commun. 2006;347:774–780
  57. Biasi F, Tessitore L, Zanetti D, Cutrin JC, Zingaro B, Chiarpotto E, et al. Associated changes of lipid peroxidation and transforming growth factor beta1 levels in human colon cancer during tumour progression. Gut. 2002;50:361–367
  58. Chiarpotto E, Scavazza A, Leonarduzzi G, Camandola S, Biasi F, Teggia PM, et al. Oxidative damage and transforming growth factor beta 1 expression in pretumoral and tumoral lesions of human intestine. Free Radic Biol Med. 1997;22:889–894

☆ Supported by grants from Compagnia di San Paolo and University of Turin (ex 60%) funds (G.B.).

PII: S0955-2863(09)00131-4

doi: 10.1016/j.jnutbio.2009.06.005

The Journal of Nutritional Biochemistry
Volume 21, Issue 9 , Pages 818-826 , September 2010

Article Tools

* Image Usage & Resolution